GlassScriptPhysician profile
Ami S Behara
NPI 1336301027
$1,705.60
in general payments reported to CMS, 2019-2025
18 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.16 · 2021: $75.18 · 2022: $12.53 · 2023: $122 · 2024: $654 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.11 | 2019-2025 | |
| Janssen Biotech, INC. | $270.28 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $259.26 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $124.98 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.72 | 2019-2023 | Xifaxan |
| Qol Medical, LLC | $78.48 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $69.49 | 2025 | Rezdiffra |
| Mauna Kea Technologies, INC. | $56.93 | 2021 | |
| Pfizer INC. | $50.94 | 2024 | |
| Celltrion USA INC. | $34.14 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $33.16 | 2025 | Omvoh |
| Ardelyx, INC. | $30.09 | 2025 | Ibsrela |
| Biocon Biologics INC | $29.63 | 2025 | Yesintek |
| Novartis Pharmaceuticals Corporation | $28.11 | 2024 | |
| Genzyme Corporation | $26.84 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $26.62 | 2024 | Rebyota |
| Vivus LLC | $15.78 | 2025 | Qsymia |
| Phathom Pharmaceuticals, INC. | $15.04 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Behara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.